HIGHLIGHTS
- who: Marije E. Hagendijk from the neuroendocrine tumour in the Netherlands have published the research: Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands, in the Journal: (JOURNAL)
- what: Methods A Markov model was developed to evaluate the costs per quality-adjusted life-year (QALY) for LO treatment compared to O-LAR from the healthcare perspective. A scenario analysis was conducted to compare the cost-effectiveness with the initial and increased price level of the LO-treatment. The aim of this . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.